ICD-10-CM Coding for Wegovy in a Patient with BMI 46.36, Hypertension, History of DVTs, and Prediabetes
The appropriate ICD-10 codes for this patient are: E66.01 (Morbid obesity due to excess calories), I10 (Essential hypertension), Z86.718 (Personal history of other venous thrombosis and embolism), and R73.03 (Prediabetes). This coding captures all relevant diagnoses that support medical necessity for Wegovy (semaglutide 2.4 mg) prescription.
Primary Diagnosis Code
E66.01 (Morbid obesity due to excess calories) is the principal diagnosis code, as this patient's BMI of 46.36 kg/m² falls into Class III obesity (morbid obesity) 1. This code is essential for insurance coverage of Wegovy, which is FDA-approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity 1.
Weight-Related Comorbidity Codes
Hypertension
I10 (Essential [primary] hypertension) documents the patient's hypertension, which is a qualifying weight-related comorbidity for Wegovy 1. This is particularly relevant as:
- Semaglutide 2.4 mg significantly reduces systolic blood pressure (mean reduction of 5.7 mmHg in STEP 8 trial) 2
- The 2024 ESC guidelines specifically recommend GLP-1 receptor agonists for weight reduction in patients with hypertension and obesity 3
- Orlistat, liraglutide, phentermine/topiramate, and semaglutide are preferred weight-loss medications in patients with existing hypertension 4
History of Deep Vein Thrombosis
Z86.718 (Personal history of other venous thrombosis and embolism) captures the DVT history. This is clinically significant because:
- The patient's history of DVTs represents a cardiovascular risk factor that may benefit from weight reduction 3
- While there are isolated case reports of DVT with GLP-1 RAs 5, a 2026 meta-analysis found that GLP-1 RAs were associated with lower VTE risk compared to DPP-4 inhibitors (HR 0.78; 95% CI 0.73-0.83) 6
- Weight loss itself reduces thrombotic risk through multiple mechanisms including improved endothelial function and reduced inflammation 7
Prediabetes
R73.03 (Prediabetes) documents the prediabetic state, which is both a qualifying comorbidity and a strong indication for semaglutide:
- Semaglutide 2.4 mg is a first-tier medication for preventing progression to overt diabetes due to substantial weight loss and direct glycemic effects 8
- In the STEP trials, semaglutide increased regression to normoglycemia by up to 84% and significantly reduced progression to diabetes 9
- The 2024 ESC guidelines recommend BP-lowering drug treatment for people with prediabetes or obesity when office BP is ≥140/90 mmHg 10
Alternative or Additional Codes to Consider
E66.9 (Obesity, unspecified) can be used if more specific obesity coding is not required, though E66.01 is more precise for this patient's BMI.
Z68.43 (Body mass index [BMI] 45.0-49.9, adult) may be added as a supplementary code to document the specific BMI value, though this is optional as the obesity diagnosis code already captures the severity.
Clinical Justification for Medical Necessity
This coding combination strongly supports medical necessity for Wegovy because:
Multiple qualifying comorbidities: The patient has at least three weight-related comorbidities (hypertension, prediabetes, history of DVT), exceeding the FDA requirement of one comorbidity for BMI ≥27 kg/m² 1
Cardiovascular risk reduction: Semaglutide 2.4 mg demonstrated a 20% reduction in cardiovascular death in the SELECT trial, which included patients with similar risk profiles 7, 3
Cardiometabolic benefits: Real-world data shows semaglutide 2.4 mg users had significantly lower risks for incident type 2 diabetes (HR 0.45-0.75), hypertension, and cardiovascular disease 11
Guideline support: The 2025 AHA/ACC guidelines and 2024 ESC guidelines both recommend GLP-1 receptor agonists for weight management in patients with obesity and cardiovascular risk factors 2, 3
Important Coding Considerations
- Do not use diabetes codes (E11.x series) unless the patient has been diagnosed with type 2 diabetes; prediabetes requires the R73.03 code
- Document failed lifestyle interventions in the medical record, as Wegovy is indicated for patients who have had inadequate response to lifestyle modifications 12, 1
- Include documentation of BMI calculation in the medical record to support the E66.01 code
- Consider adding Z79.84 (Long-term use of oral hypoglycemic drugs) if the patient is on metformin for prediabetes, though this is not required for Wegovy coding